GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Professor of Internal Medicine

      The purpose of this study it to determine whether the use of a gonadotropin releasing hormone
      (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in women with
      rheumatic diseases will provide greater ovarian protection than placebo.
    
Drug